VectivBio Holding AG
VECT
Cena:
Valuace
70
Růst
30
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
0
IRONWOOD AND VECTIVBIO ANNOUNCE THE COMPLETION OF THE TENDER OFFER FOR VECTIVBIO SHARES
29-06-2023
BOSTON & BASEL, SWITZERLAND--(BUSINESS WIRE)--IRONWOOD PHARMACEUTICALS, INC. (“IRONWOOD”) (NASDA...
Více zde
VECTIVBIO EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS APPROVED ALL PROPOSALS
26-06-2023
BASEL, SWITZERLAND, JUNE 26, 2023 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
IRONWOOD AND VECTIVBIO ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR PROPOSED ACQUISITION OF VECTIVBIO
16-06-2023
BOSTON & BASEL, SWITZERLAND--(BUSINESS WIRE)--IRONWOOD PHARMACEUTICALS, INC. (“IRONWOOD”) (NASDA...
Více zde
VECTIVBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF VECTIVBIO HOLDING AG - VECT
06-06-2023
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND TH...
Více zde
VECTIVBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF VECTIVBIO HOLDING AG - VECT
25-05-2023
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND TH...
Více zde
VECT STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF VECTIVBIO HOLDING AG IS FAIR TO SHAREHOLDERS
22-05-2023
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
IRONWOOD ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE VECTIVBIO, A CLINICAL-STAGE BIOTECH COMPANY PIONEERING NOVEL TREATMENTS FOR SEVERE RARE GASTROINTESTINAL DISEASES
22-05-2023
BOSTON & BASEL, SWITZERLAND--(BUSINESS WIRE)--IRONWOOD PHARMACEUTICALS, INC. (“IRONWOOD”) (NASDA...
Více zde
VECTIVBIO REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
19-04-2023
CONTINUED STRONG PROGRESS AND MOMENTUM ACROSS MULTIPLE PROGRAMS WITH KEY UPCOMING DATA MILESTONES ...
Více zde
VECTIVBIO AND ASAHI KASEI PHARMA ANNOUNCE THE START OF A PHASE 1 STUDY OF APRAGLUTIDE IN JAPAN
13-03-2023
SINGLE-DOSE STUDY TO ASSESS PHARMACOKINETICS, PHARMACOLOGICAL ACTIVITY, SAFETY AND TOLERABILITY IN H...
Více zde
VECTIVBIO ANNOUNCES RESULTS OF EXTRAORDINARY GENERAL MEETING
09-12-2022
-WOUTER JOUSTRA ELECTED TO THE BOARD OF DIRECTORS -WOUTER JOUSTRA ELECTED TO THE BOARD OF DIRECTORS...
Více zde
VECTIVBIO PUBLISHES INVITATION TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
16-11-2022
BASEL, SWITZERLAND, NOV. 16, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO TO PRESENT AT THE 2022 JEFFERIES LONDON HEALTHCARE CONFERENCE
09-11-2022
BASEL, SWITZERLAND, NOV. 09, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES COMPLETION OF ENROLLMENT FOR COLON-IN-CONTINUITY (CIC) COHORT OF STARS PIVOTAL PHASE 3 STUDY INVESTIGATING APRAGLUTIDE IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF)
03-11-2022
-LARGEST GLOBAL PHASE 3 STUDY EVER CONDUCTED IN SBS-IF RECRUITING A TOTAL OF 144 PATIENTS, STRATIFIE...
Více zde
VECTIVBIO ANNOUNCES CLOSING OF $125 MILLION UNDERWRITTEN OFFERING OF ORDINARY SHARES
18-10-2022
BASEL, SWITZERLAND, OCT. 18, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES PRICING OF $125 MILLION UNDERWRITTEN OFFERING OF ORDINARY SHARES
13-10-2022
BASEL, SWITZERLAND, OCT. 13, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO REPORTS POSITIVE INTERIM CLINICAL DATA FROM STARS NUTRITION, A PHASE 2 STUDY INVESTIGATING APRAGLUTIDE IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE PATIENTS (SBS-IF) WITH COLON-IN-CONTINUITY (CIC)
13-10-2022
• TREATMENT WITH APRAGLUTIDE RESULTED IN AN AVERAGE 50% REDUCTION IN PARENTERAL SUPPORT (PS) VOL...
Více zde
VECTIVBIO ANNOUNCES DATE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
12-10-2022
BASEL, SWITZERLAND, OCT. 12, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES CLOSING OF $54 MILLION AGGREGATE FINANCING
29-06-2022
BASEL, SWITZERLAND, JUNE 29, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES PRICING OF $30 MILLION PUBLIC OFFERING OF ORDINARY SHARES
14-06-2022
COMBINED GROSS PROCEEDS FROM PUBLIC OFFERING AND PRIVATE SALE TOTAL $50 MILLION COMBINED GROSS PROCE...
Více zde
VECTIVBIO ANNOUNCES LAUNCH OF PUBLIC OFFERING OF ORDINARY SHARES
14-06-2022
BASEL, SWITZERLAND, JUNE 14, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO PUBLISHES INVITATION TO THE ANNUAL GENERAL MEETING
09-06-2022
BASEL, SWITZERLAND, JUNE 09, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES FIRST TWO PATIENTS DOSED IN PHASE 2 STARGAZE STUDY OF APRAGLUTIDE FOR THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
02-06-2022
– INTERIM PROOF-OF-CONCEPT DATA ANTICIPATED FROM STARGAZE IN H1 2023...
Více zde
VECTIVBIO TO PARTICIPATE AT THE BANK OF AMERICA 2022 HEALTHCARE CONFERENCE
09-05-2022
BASEL, SWITZERLAND, MAY 09, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ:...
Více zde
VECTIVBIO APPOINTS PATRICK MALLOY AS SENIOR VICE PRESIDENT, INVESTOR RELATIONS & STRATEGIC COMMUNICATIONS
21-04-2022
ARENA PHARMACEUTICALS AND ACTELION VETERAN BRINGS DEEP INDUSTRY EXPERIENCE AS VECTIVBIO PREPARES FO...
Více zde
VECTIVBIO REPORTS FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
07-04-2022
SIGNIFICANT PROGRESS ACROSS MULTIPLE PROGRAMS WITH KEY UPCOMING CATALYSTS BEGINNING H2 2022...
Více zde
VECTIVBIO ANNOUNCES JAPAN LICENSE DEAL AND LOAN FACILITY AGREEMENT, PROVIDING UP TO $117 MILLION TO FUEL THE COMPANY THROUGH KEY CATALYSTS
30-03-2022
BASEL, SWITZERLAND, MARCH 30, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDA...
Více zde
VECTIVBIO PRESENTS PRECLINICAL DATA SUPPORTING APRAGLUTIDE FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE AT THE 48TH ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION
23-03-2022
-- APRAGLUTIDE, A NEXT-GENERATION GLP-2 ANALOG, PROTECTED AGAINST CHEMOTHERAPY-INDUCED GASTROINTESTI...
Více zde
VECTIVBIO TO PRESENT AT THE SVB LEERINK 11TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
08-02-2022
BASEL, SWITZERLAND, FEB. 08, 2022 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
VECTIVBIO ANNOUNCES THIRD QUARTER 2021 BUSINESS UPDATE
10-11-2021
-PIVOTAL STARS PROGRAM OF APRAGLUTIDE IN SBS-IF PROGRESSING WITH MAJORITY OF SITES ACTIVATED AND SCR...
Více zde
VECTIVBIO TO PRESENT AT THE CREDIT SUISSE 30TH ANNUAL HEALTHCARE CONFERENCE
04-11-2021
BASEL, SWITZERLAND, NOV. 04, 2021 (GLOBE NEWSWIRE) -- VECTIVBIO HOLDING AG (“VECTIVBIO”) (NASDAQ...
Více zde
Dokumenty nejsou k dispozici
